IOL Chemicals and Pharmaceuticals (IOLCP) has received from US Food and Drug Administration (USFDA), Establishment Inspection Report after successful inspection of its Ibuprofen manufacturing facility situated at Barnala, Punjab, India.
Post this approval, the company will be able to garner additional business for its flagship API Ibuprofen in World's largest pharma market-USA. This will result into higher value added export turnover and higher margins.
The company’s manufacturing facility already holds CEP certification (Certificate of Suitability) for its products Ibuprofen, Metformin Hydrochloride & Lamotrigine from European Directorate for the Quality of Medicines & HealthCare (EDQM) authorities, Council of Europe, France. The said facility at Barnala has also been approved by ANVISA Brazil, WHO & MOH Japan.
These approvals will help the company to build and sustaining the growth by its API business in coming years, being the only integrated player globally, by exploring the higher value added regulated markets.
